NRX Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY EPS (est.)
-$0.36next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly6.7MTarget: Sufficient to support operations through 2026
Net Loss Quarterly-1.4MTarget: Achieve breakeven by FY 2027
Clinical Trial Evidence Database (Osmind Partnership) Annually65KTarget: Support NDA filing for NRX-100
Watch Items
- FDA ANDA Approval for KETAFREE™ (Preservative-Free Ketamine)Trigger: FDA decision expected in Q3 2026Action: Initiate commercial sales and launch product upon approval
- New Drug Application (NDA) Submission for NRX-100Trigger: Submission targeted by June 2026 / Q2 2026Action: Complete and file the NDA with the FDA
- Phase 2/3 Clinical Development of NRX-101Trigger: Completion of genotoxicity and non-clinical maternal/fetal studiesAction: Advance clinical trials and explore strategic partnership options
Research as of 19 Jun 2026